| Description | CHD1Li 6.11 is a potent inhibitor of oncogenic CHD1L, acting on the cat-CHD1L recombinant protein (IC50: 3.3 μM). CHD1Li 6.11 is an orally active antitumour agent that significantly reduces the tumour volume of CRC xenografts generated from isolated quasi-mesenchymal cells (M phenotype) with enhanced tumourigenic properties. These cells have enhanced tumourigenic properties. |
| Target activity | Catalytic CHD1L:3.3 µM |
| molecular weight | 472.4 |
| Molecular formula | C21H22BrN5OS |
| CAS | 2716890-91-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 90.0 mg/mL (190.5 mM ), Sonication is recommended. |
| References | 1. Prigaro BJ, et al. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022;65(5):3943-3961. |